The DOI matches its Crossref record; 216 of the 216 references it cites were found in a registry or an index.
Cognitive decline in Parkinson disease
Open accessAbstract
Dementia is a frequent problem encountered in advanced stages of Parkinson disease (PD). In recent years, research has focused on the pre-dementia stages of cognitive impairment in PD, including mild cognitive impairment (MCI). Several longitudinal studies have shown that MCI is a harbinger of dementia in PD, although the course is variable, and stabilization of cognition - or even reversal to normal cognition - is not uncommon. In addition to limbic and cortical spread of Lewy pathology, several other mechanisms are likely to contribute to cognitive decline in PD, and a variety of biomarker studies, some using novel structural and functional imaging techniques, have documented in vivo brain changes associated with cognitive impairment. The evidence consistently suggests that low cerebrospinal fluid levels of amyloid-β 42, a marker of comorbid Alzheimer disease (AD), predict future cognitive decline and dementia in PD. Emerging genetic evidence indicates that in addition to the APOE*ε4 allele (an established risk factor for AD), GBA mutations and SCNA mutations and triplications are associated with cognitive decline in PD, whereas the findings are mixed for MAPT polymorphisms. Cognitive enhancing medications have some effect in PD dementia, but no convincing evidence that progression from MCI to dementia can be delayed or prevented is available, although cognitive training has shown promising results.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Moreover there are several candidate genetic risk factors that overlap for AD and PD, most notably APOE and MAPT [127].”
From The neuropathological diagnosis of Alzheimer's disease (2019) · cites this paper as [127]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Staging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777
MDS clinical diagnostic criteria for Parkinson’s disease
Postuma, R. B., Berg, D., Stern, M., Poewe, W., Olanow, C. W., Oertel, W., Obeso, J., Marek, K., Litvan, I., Lang, A. E., et al. (2015) · Movement Disorders · doi:10.1002/mds.26424 · Cited by 7,653
Terry, R. D., Masliah, E., Salmon, D. P., Butters, N., DeTeresa, R., Hill, R., Hansen, L. A., & Katzman, R. (1991) · Annals of Neurology · doi:10.1002/ana.410300410 · Cited by 4,397
Clinical diagnostic criteria for dementia associated with Parkinson’s disease
Emre, M., Aarsland, D., Brown, R., Burn, D. J., Duyckaerts, C., Mizuno, Y., Broe, G. A., Cummings, J., Dickson, D. W., Gauthier, S., et al. (2007) · Movement Disorders · doi:10.1002/mds.21507 · Cited by 3,027
Self-citationLitvan, I., Goldman, J. G., Tröster, A. I., Schmand, B. A., Weintraub, D., Petersen, R. C., Mollenhauer, B., Adler, C. H., Marder, K., Williams‐Gray, C. H., et al. (2012) · Movement Disorders · doi:10.1002/mds.24893 · Cited by 2,609
Self-citationThe Sydney multicenter study of Parkinson's disease: The inevitability of dementia at 20 years
Hely, M. A., Reid, W. G. J., ADENA, M. A., Halliday, G. M., & Morris, J. G. (2008) · Movement Disorders · doi:10.1002/mds.21956 · Cited by 2,346
α-synuclein locus duplication as a cause of familial Parkinson's disease
Chartier-Harlin, M.-C., Kachergus, J., Roumier, C., Mouroux, V., Douay, X., Lincoln, S., Levecque, C., Larvor, L., Andrieux, J., Hulihan, M., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17103-1 · Cited by 2,029
Healy, D. G., Falchi, M., O'Sullivan, S. S., Bonifati, V., Durr, A., Bressman, S., Brice, A., Aasly, J., Zabetian, C. P., Goldwurm, S., et al. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70117-0 · Cited by 1,425
Prevalence and Characteristics of Dementia in Parkinson Disease
Aarsland, D., Andersen, K., Larsen, J. O., & Lolk, A. (2003) · Archives of Neurology · doi:10.1001/archneur.60.3.387 · Cited by 1,403
Self-citationMultimodal classification of Alzheimer's disease and mild cognitive impairment
Zhang, D., Wang, Y., Zhou, L., Yuan, H., & Shen, D. G. (2011) · NeuroImage · doi:10.1016/j.neuroimage.2011.01.008 · Cited by 1,340
Cited by
Sorted by citations
Items 201–300 of 1,000
Analysis of Gait for Disease Stage in Patients with Parkinson’s Disease
Vila, H., Pérez, R., Mollinedo-Cardalda, I., & Carral, J. M. C. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18020720 · Cited by 35
Parkinson’s Disease Dementia: Synergistic Effects of Alpha-Synuclein, Tau, Beta-Amyloid, and Iron
Han, J., Fan, Y., Wu, P., Huang, Z., Li, X., Zhao, L., Ji, Y., & Zhu, M. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.743754 · Cited by 36
Mantovani, E., Zucchella, C., Argyriou, A. A., & Tamburin, S. (2023) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2023.2173576 · Cited by 35
Martínez‐Martín, P., & Chaudhuri, К. R. (2017) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2018.1400383 · Cited by 34
Stojković, T., Stefanova, E. D., Soldatović, I., Marković, V., Stanković, I., Petrović, I. N., Agosta, F., Galantucci, S., Filippi, M., & Kostić, V. (2018) · Journal of Neurology · doi:10.1007/s00415-018-8838-3 · Cited by 34
Weiss, A., Herman, T., Mirelman, A., Shema-Shiratzky, S., Giladi, N., Barnes, L. L., Bennett, D. A., Buchman, A. S., & Hausdorff, J. M. (2018) · Gait & Posture · doi:10.1016/j.gaitpost.2018.10.018 · Cited by 34
The influence of white matter hyperintensity on cognitive impairment in Parkinson's disease
Liu, H., Deng, B., Xie, F., Yang, X., Xie, Z., Chen, Y., Yang, Z., Huang, X., Zhu, S., & Wang, Q. (2021) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51429 · Cited by 34
Yi, G., Wang, L., Chu, C., Liu, C., Zhu, X., Shen, X. X., Li, Z., Wang, F., Yang, M., & Wang, J. (2021) · Cognitive Neurodynamics · doi:10.1007/s11571-021-09722-w · Cited by 34
Chalcones as Potential Ligands for the Treatment of Parkinson’s Disease
Królicka, E., Kieć‐Kononowicz, K., & Łażewska, D. (2022) · Pharmaceuticals · doi:10.3390/ph15070847 · Cited by 34
Becker, S., Bode, M., Brockmann, K., Gasser, T., Michaelis, K., Solbrig, S., Nuerk, H., Schulte, C., Maetzler, W., Zimmermann, M., et al. (2022) · Neurology · doi:10.1212/wnl.0000000000201201 · Cited by 33
Jenner, P. G., Mori, A., & Kanda, T. (2020) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2020.09.022 · Cited by 34
The Potential Role of Protein Kinase R as a Regulator of Age-Related Neurodegeneration
Martínez, N. W., Gómez, F. E., & Matus, S. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.638208 · Cited by 31
Yang, Y., Chen, L., Pang, J., Huang, X., Meng, L., & Ming, D. (2022) · IEEE Transactions on Biomedical Engineering · doi:10.1109/tbme.2022.3172725 · Cited by 33
Distinct Bile Acid Signature in Parkinson's Disease With Mild Cognitive Impairment
Nie, K., Li, Y., Zhang, J., Gao, Y., Qiu, Y., Gan, R., Zhang, Y., & Wang, L. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.897867 · Cited by 33
Dopaminergic degeneration induces early posterior cortical thinning in Parkinson's disease
Sampedro, F., Marín‐Lahoz, J., Martínez‐Horta, S., Pagonabarraga, J., & Kulisevsky, J. (2018) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.11.001 · Cited by 33
Contribution of amyloid deposition from oligodendrocytes in a mouse model of Alzheimer’s disease
Ishii, A., Pathoulas, J., Omar, O. M., Ge, Y., Yao, A. Y., Pantalena, T., Singh, N., Zhou, J., He, W., Murphy, P. A., et al. (2024) · Molecular Neurodegeneration · doi:10.1186/s13024-024-00759-z · Cited by 31
Clinical and Cerebral Metabolic Changes in Parkinson's Disease With Basal Forebrain Atrophy
Gang, M., Baba, T., Hosokai, Y., Nishio, Y., Kikuchi, A., Hirayama, K., Hasegawa, T., Aoki, M., Takeda, A., Mori, E., et al. (2020) · Movement Disorders · doi:10.1002/mds.27988 · Cited by 35
Söderbom, G., & Zeng, B. (2020) · International review of neurobiology · doi:10.1016/bs.irn.2020.03.023 · Cited by 32
Cortés, A., Solas, M., Pejenaute, Á., Abellanas, M. A., Garcia-Lacarte, M., Aymerich, M. S., Marqués, J., Ramírez, M. J., & Zalba, G. (2021) · Antioxidants · doi:10.3390/antiox10081311 · Cited by 32
Charissé, D., Erus, G., Pomponio, R., Gorges, M., Schmidt, N., Schneider, C. B., Liepelt‐Scarfone, I., Riedel, O., Reetz, K., Schulz, J. B., et al. (2021) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2021.08.020 · Cited by 31
Cholinergic Receptor Modulation as a Target for Preventing Dementia in Parkinson’s Disease
Iarkov, A., Mendoza, C., & Echeverrı́a, V. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.665820 · Cited by 36
Weinshel, S., Irwin, D. J., Zhang, P., Weintraub, D. A., Shaw, L. M. J., Siderowf, A. D., & Xie, S. X. (2022) · Journal of Parkinson s Disease · doi:10.3233/jpd-212989 · Cited by 32
Self-citationZawiślak-Fornagiel, K., Ledwoń, D. J., Bugdol, M. N., Romaniszyn‐Kania, P., Małecki, A., Gorzkowska, A., & Mitas, A. W. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12041569 · Cited by 30
Long, C., Han, X., Yang, Y., Li, T., Zhou, Q., & Chen, Q. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.963933 · Cited by 31
Trends and hotspots in non-motor symptoms of Parkinson’s disease: a 10-year bibliometric analysis
Li, X., Chen, C., Pan, T., Zhou, X., Sun, X., Zhang, Z., Wu, D., & Chen, X. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1335550 · Cited by 37
Khan, A., Ezeugwa, J. C., & Ezeugwu, V. E. (2024) · PLoS ONE · doi:10.1371/journal.pone.0293382 · Cited by 31
Parkinson's disease subtypes: Approaches and clinical implications
Deng, X., Mehta, A., Xiao, B., Chaudhuri, К. R., Tan, E., & Tan, L. C. (2024) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2024.107208 · Cited by 41
Novel models for Parkinson’s disease and their impact on future drug discovery
Trigo‐Damas, I., del Rey, N. L., & Blesa, J. (2018) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2018.1428556 · Cited by 31
Genetic modifiers of age-at-onset in polyglutamine diseases
Chen, Z., Sequeiros, J., Tang, B., & Jiang, H. F. (2018) · Ageing Research Reviews · doi:10.1016/j.arr.2018.10.004 · Cited by 32
Green, H., Tsitsi, P., Markaki, I., Aarsland, D., & Svenningsson, P. (2019) · CNS Drugs · doi:10.1007/s40263-018-0601-x · Cited by 31
Self-citationDroby, A., Maidan, I., Jacob, Y., Giladi, N., Hausdorff, J. M., & Mirelman, A. (2020) · Neurorehabilitation and neural repair · doi:10.1177/1545968320940985 · Cited by 31
Compartmentalized Signaling in Aging and Neurodegeneration
Benedetto, G. D., Iannucci, L. F., Surdo, N. C., Zanin, S., Conca, F., Grisan, F., Gerbino, A., & Lefkimmiatis, K. (2021) · Cells · doi:10.3390/cells10020464 · Cited by 30
Human moral decision-making through the lens of Parkinson’s disease
Ponsi, G., Scattolin, M., Villa, R., & Aglioti, S. M. (2021) · npj Parkinson s Disease · doi:10.1038/s41531-021-00167-w · Cited by 32
Schindlbeck, K. A., Vo, A., Mattis, P. J., Villringer, K., Marzinzik, F., Fiebach, J. B., & Eidelberg, D. (2021) · Cerebral Cortex · doi:10.1093/cercor/bhab148 · Cited by 31
Torghabeh, F. A., Hosseini, S. A., & Moghadam, E. A. (2023) · Medicine in Novel Technology and Devices · doi:10.1016/j.medntd.2023.100266 · Cited by 31
Ogonowski, N. S., García‐Marín, L. M., Fernando, A. S., Flores‐Ocampo, V., & Rentería, M. E. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-02898-9 · Cited by 31
Paradoxical Decision-Making: A Framework for Understanding Cognition in Parkinson’s Disease
Perugini, A., Ditterich, J., Shaikh, A. G., Knowlton, B. J., & Basso, M. A. (2018) · Trends in Neurosciences · doi:10.1016/j.tins.2018.04.006 · Cited by 31
Mostile, G., Giuliano, L., Monastero, R., Luca, A., Cicero, C. E., Donzuso, G., Dibilio, V., Baschi, R., Terranova, R., Restivo, V., et al. (2019) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2019.03.027 · Cited by 29
Ceccarini, J., Casteels, C., Ahmad, R. U., Crabbé, M., de Vliet, L. V., Vanhaute, H., Vandenbulcke, M., Vandenberghe, W., & Laere, K. V. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04445-x · Cited by 31
Cerqueira, T. M. D. M., de Moura, J. A., de Lira, J. O., Leal, J. C., D’Amelio, M., & Mendes, F. A. D. S. (2019) · Physiotherapy Research International · doi:10.1002/pri.1807 · Cited by 30
Bellomo, G., Paoletti, F. P., Chipi, E., Petricciuolo, M., Simoni, S., Tambasco, N., & Parnetti, L. (2020) · Diagnostics · doi:10.3390/diagnostics10121015 · Cited by 30
Region-Specific Neurovascular Decoupling Associated With Cognitive Decline in Parkinson’s Disease
Shang, S., Zhang, H., Feng, Y., Wu, J., Dou, W., Chen, Y., & Yin, X. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.770528 · Cited by 30
Wang, K., Xu, L., Liu, L., Zhan, S., Wang, S., & Song, Y. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.08.014 · Cited by 30
Perry, S. I. B., Nelissen, P., Siemonsma, P. C., & Lucas, C. (2018) · Complementary Therapies in Medicine · doi:10.1016/j.ctim.2018.12.008 · Cited by 32
T2*-weighted MRI values correlate with motor and cognitive dysfunction in Parkinson's disease
Tambasco, N., Paoletti, F. P., Chiappiniello, A., Lisetti, V., Nigro, P., Eusebi, P., Chiarini, P., Romoli, M., Brahimi, E., Simoni, S., et al. (2019) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2019.04.005 · Cited by 29
Ophey, A., Giehl, K., Rehberg, S., Eggers, C., Reker, P., van Eimeren, T., & Kalbe, E. (2020) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2020.02.002 · Cited by 30
Theta and gamma connectivity is linked with affective and cognitive symptoms in Parkinson's disease
Iyer, K. K., Au, T. R., Angwin, A. J., Copland, D. A., & Dissanayaka, N. N. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.08.086 · Cited by 28
Increased homocysteine levels correlate with cortical structural damage in Parkinson's disease
Sampedro, F., Martínez‐Horta, S., Horta‐Barba, A., Grothe, M. J., Labrador‐Espinosa, M. Á., Jesús, S., Adarmes-Gómez, A. D., Carrillo, F., Puig‐Davi, A., Lora, F. R., et al. (2022) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2022.120148 · Cited by 29
Hou, L., Liu, J., Sun, F., Huang, R., Chang, R., Ruan, Z., Wang, Y., Zhao, J., & Wang, Q. (2023) · Journal of Neuroinflammation · doi:10.1186/s12974-023-02732-x · Cited by 30
Guttuso, T. J., Andrzejewski, K. L., Lichter, D. G., & Andersen, J. K. (2019) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2019.05.016 · Cited by 29
NeuroVoz: a Castillian Spanish corpus of parkinsonian speech
Mendes-Laureano, J., Gómez-García, J. A., Guerrero-López, A., Luque‐Buzo, E., Arias-Londoño, J. D., Grandas, F., & Godino-Llorente, J. I. (2024) · Scientific Data · doi:10.1038/s41597-024-04186-z · Cited by 29
Chen, X., & Zhang, Y. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.379042 · Cited by 29
Resting State fMRI: A Valuable Tool for Studying Cognitive Dysfunction in PD
Li, K., Su, W., Li, S.-H., Jin, Y., & Chen, H. (2018) · Parkinson s Disease · doi:10.1155/2018/6278649 · Cited by 28
Νούσια, Α., Μαρτζούκου, Μ., Tsouris, Z., Siokas, V., Aloizou, A., Liampas, I., Nasios, G., & Dardiotis, E. (2019) · Archives of Clinical Neuropsychology · doi:10.1093/arclin/acz080 · Cited by 28
Nimmons, D., Hatter, L., Davies, N., Sampson, E. L., Walters, K. R., & Schrag, A. E. (2020) · European Journal of Neurology · doi:10.1111/ene.14424 · Cited by 28
Frontostriatal and limbic contributions to cognitive decline in Parkinson's disease
Brown, G., Hakun, J. G., Lewis, M. M., Jesus, S. D., Du, G., Eslinger, P. J., Kong, L., & Huang, X. (2022) · Journal of Neuroimaging · doi:10.1111/jon.13045 · Cited by 28
McFall, G. P., Bohn, L., Gee, M., Drouin, S. M., Fah, H., Han, W., Li, L., Camicioli, R. M., & Dixon, R. A. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1124232 · Cited by 29
Nonmotor Subtyping in Parkinson's Disease
Sauerbier, A., Rosa‐Grilo, M., Qamar, M. A., & Chaudhuri, К. R. (2017) · International review of neurobiology · doi:10.1016/bs.irn.2017.05.011 · Cited by 28
Gjerde, K. V., Müller, B., SKEIE, G. O., Aßmus, J., Alves, G. W., & Tysnes, O. (2018) · Acta Neurologica Scandinavica · doi:10.1111/ane.13003 · Cited by 28
Ciranna, L., & Costa, L. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00524 · Cited by 30
Peláez Suárez, A. A., Berrillo Batista, S., Pedroso Ibáñez, I., Casabona Fernández, E., Fuentes Campos, M., & Chacón, L. M. (2021) · Behavioral Sciences · doi:10.3390/bs11030040 · Cited by 27
Tzvetkov, N. T., Stammler, H., Hristova, S., Atanasov, A. G., & Antonov, L. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.11.009 · Cited by 27
Zheng, D., Chen, C., Song, W., Yi, Z., Zhao, P., Zhong, J., Dai, Z., Shi, H., & Pan, P. (2019) · Behavioural Brain Research · doi:10.1016/j.bbr.2019.111973 · Cited by 26
Autonomic dysfunction is associated with neuropsychological impairment in Lewy body disease
Pino, R. D., Murueta‐Goyena, A., Acera, M., Carmona‐Abellán, M., Tijero, B., Lucas‐Jiménez, O., Ojeda, N., Ibarretxe‐Bilbao, N., Peña, J., Gabilondo, I., et al. (2020) · Journal of Neurology · doi:10.1007/s00415-020-09783-7 · Cited by 27
Predicting the onset of freezing of gait in Parkinson’s disease
Wang, F., Pan, Y., Zhang, M., & Hu, K. (2022) · BMC Neurology · doi:10.1186/s12883-022-02713-2 · Cited by 27
Donahue, E. K., Venkadesh, S., Bui, V., Tuazon, A. C., Wang, R. K., Haase, D., Foreman, R. P., Duran, J. J., Petkus, A. J., Wing, D., et al. (2022) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2022.09.005 · Cited by 27
Therapeutic potential of targeting kynurenine pathway in neurodegenerative diseases
Shen, H., Xu, X., Bai, Y., Wang, X., Wu, Y., Zhong, J., Wu, Q., Luo, Y., Shang, T., Shen, R., et al. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115258 · Cited by 27
Tang, C., Liu, M., Zhou, Z., Li, H., Yang, C., Yang, L., & Xiang, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24097830 · Cited by 27
Sekino, Y., Han, X., Babasaki, T., Goto, K., Inoue, S., Hayashi, T., Teishima, J., Shiota, M., Takeshima, Y., Yasui, W., et al. (2020) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2020.04.032 · Cited by 27
Hepp, D. H., van Wageningen, T. A., Kuiper, K. L., van Dijk, K. D., Oosterveld, L. P., Berendse, H. W., & van de Berg, W. D. J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914915 · Cited by 28
Tan, J., Laurell, A. A. S., Sidhom, E., Rowe, J. B., & O'Brien, J. T. (2024) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2024.107255 · Cited by 26
Hermann, W., Schmitz‐Peiffer, H., Kasper, E., Fauser, M., Franke, C., Wienecke, M., Otto, K., Löhle, M., Brandt, M., Reichmann, H., et al. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00689 · Cited by 26
Kalbe, E., Folkerts, A., Ophey, A., Eggers, C., Elben, S., Dimenshteyn, K., Sulzer, P., Schulte, C., Schmidt, N., Schlenstedt, C., et al. (2020) · Parkinson s Disease · doi:10.1155/2020/4068706 · Cited by 26
Progression of Nonmotor Symptoms in Parkinson’s Disease by Sex and Motor Laterality
Kurlawala, Z., Shadowen, P. H., McMillan, J. D., Beverly, L. J., & Friedland, R. P. (2021) · Parkinson s Disease · doi:10.1155/2021/8898887 · Cited by 26
van Balkom, T. D., Berendse, H. W., van der Werf, Y. D., Twisk, J. W. R., Peeters, C. F. W., Hoogendoorn, A. W., Hagen, R. H., Berk, T., van den Heuvel, O. A., & Vriend, C. (2022) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2022.02.018 · Cited by 26
Yang, C., Wang, W., Deng, P., Wang, X., Zhu, L., Zhao, L., Li, C., & Gao, H. (2023) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14302 · Cited by 26
Kokubo, N., Yokoi, Y., Saitoh, Y., Murata, M., Maruo, K., Takebayashi, Y., Shinmei, I., Yoshimoto, S., & Horikoshi, M. (2018) · BMC Psychiatry · doi:10.1186/s12888-018-1795-7 · Cited by 26
Genetic and Environmental Factors Influence the Pleomorphy of LRRK2 Parkinsonism
Chittoor-Vinod, V. G., Nichols, R. J., & Schüle, B. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22031045 · Cited by 26
Bai, W., An, S., Jia, H. M., Xu, J., & Qin, L. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1398235 · Cited by 27
Kalbe, E., Folkerts, A., Witt, K., Buhmann, C., Liepelt‐Scarfone, I., & for the German Parkinson’s Guidelines Group (2024) · Journal of Neurology · doi:10.1007/s00415-024-12503-0 · Cited by 25
Mantovani, E., Martini, A., Dinoto, A., Zucchella, C., Ferrari, S., Mariotto, S., Tinazzi, M., & Tamburin, S. (2024) · npj Parkinson s Disease · doi:10.1038/s41531-024-00823-x · Cited by 29
Non-pharmacological management of cognitive impairment in Parkinson’s disease
Pupíková, M., & Rektorová, I. (2019) · Journal of Neural Transmission · doi:10.1007/s00702-019-02113-w · Cited by 25
Meynert nucleus-related cortical thinning in Parkinson’s disease with mild cognitive impairment
Rong, S., Li, Y., Li, B., Nie, K., Zhang, P., Cai, T., Mei, M., Wang, L., & Zhang, Y. (2021) · Quantitative Imaging in Medicine and Surgery · doi:10.21037/qims-20-444 · Cited by 25
Zhu, Y., Yang, B., Wang, F., Liu, B., Li, K., Yin, K., Yin, W. F., Zhou, C., Tian, S., Ren, H. J., et al. (2021) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2021.577662 · Cited by 25
Martínez‐Horta, S., Bejr‐Kasem, H., Horta‐Barba, A., Pascual‐Sedano, B., Santos‐García, D., de Deus-Fonticoba, T., Jesús, S., Aguilar, M., Planellás, L., García‐Caldentey, J., et al. (2021) · BMC Neurology · doi:10.1186/s12883-021-02485-1 · Cited by 25
Wang, L., Zhou, C., Cheng, W., Rolls, E. T., Huang, P., Ma, N., Liu, Y., Zhang, Y., Guan, X., Guo, T., et al. (2021) · Human Brain Mapping · doi:10.1002/hbm.25745 · Cited by 27
Peng, S., Zhou, J. H., Xiong, S., Liu, X., Pei, M., Wang, Y., Wang, X., & Zhang, P. (2023) · BMC Psychiatry · doi:10.1186/s12888-023-04736-6 · Cited by 29
Changes in electrophysiological aperiodic activity during cognitive control in Parkinson’s disease
Monchy, N., Modolo, J., Houvenaghel, J., Voytek, B., & Duprez, J. (2024) · Brain Communications · doi:10.1093/braincomms/fcae306 · Cited by 29
Biomarkers for cognitive impairment in Lewy body disorders: Status and relevance for clinical trials
Siderowf, A. D., Aarsland, D., Mollenhauer, B., Goldman, J. G., & Ravina, B. M. (2018) · Movement Disorders · doi:10.1002/mds.27355 · Cited by 25
Self-citationAdvantages of Vasoactive Intestinal Peptide for the Future Treatment of Parkinson’s Disease
Korkmaz, O. T., & Tunçel, N. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190111150953 · Cited by 25
Levodopa-induced dyskinesia is closely linked to progression of frontal dysfunction in PD
Yoo, H. S., Chung, S. J., Lee, Y. H., Lee, H. S., Ye, B. S., Sohn, Y. H., & Lee, P. H. (2019) · Neurology · doi:10.1212/wnl.0000000000007189 · Cited by 25
Shen, J., Xie, J., Ye, L., Mao, J., Sun, S., Chen, W., Wei, S., Ruan, S., Wang, L., Hu, H., et al. (2024) · Neuroreport · doi:10.1097/wnr.0000000000002027 · Cited by 25
Wu, X., Tang, Y., He, Y., Wang, Q., Wang, Y., & Qin, X. (2024) · Frontiers in Public Health · doi:10.3389/fpubh.2024.1500172 · Cited by 24
Hill, A. T., McModie, S., Fung, W. K. W., Hoy, K. E., Chung, S. W., & Bertram, K. (2019) · Brain Research · doi:10.1016/j.brainres.2019.146506 · Cited by 25
Ramezani, M., Mouchès, P., Yoon, E., Rajashekar, D., Ruskey, J. A., Léveillé, E., Martens, K., Kibreab, M., Hammer, T., Kathol, I., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-84316-4 · Cited by 24
van den Hurk, W., Bergman, I., Machado, A., Bjermo, J., & Gustavsson, A. (2021) · Journal of the International Neuropsychological Society · doi:10.1017/s135561772100045x · Cited by 25
Machine learning can predict mild cognitive impairment in Parkinson's disease
Amboni, M., Ricciardi, C., Adamo, S., Nicolai, E., Volzone, A., Erro, R., Cuoco, S., Cesarelli, G., Basso, L., D’Addio, G., et al. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.1010147 · Cited by 24
Lerche, S., Zimmermann, M., Röeben, B., Wurster, I., Fries, F. L., Deuschle, C., Waniek, K., Lachmann, I., Jakobi, M., Joos, T. O., et al. (2023) · npj Parkinson s Disease · doi:10.1038/s41531-023-00476-2 · Cited by 29
Donahue, E. K., Foreman, R. P., Duran, J. J., Jakowec, M. W., O’Neill, J., Petkus, A. J., Holschneider, D. P., Choupan, J., Horn, J. D. V., Venkadesh, S., et al. (2023) · Brain Imaging and Behavior · doi:10.1007/s11682-023-00811-4 · Cited by 25
Association between triglyceride glucose index and cognitive decline: A meta-analysis
Liu, Y., Yang, X., Gao, J., Xie, C., Tian, C., & Gao, T. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.05.049 · Cited by 24
Metadata
- Authors
- Aarsland, D., Creese, B., Politis, M., Chaudhuri, K. R., ffytche, D. H., Weintraub, D., & Ballard, C.
- Affiliations
- King's College London (GB)
- Corresponding author
- Aarsland, Dag
- Venue
- Nature Reviews Neurology
- Published
- 2017-03-03
- Volume
- 13
- Issue
- 4
- Pages
- 217-231
- ISSN
- 1759-4758 (ISSN-L)
- 1759-4766
- PMC
- PMC5643027
- OpenAlex
- W2593272776
- Cited by
- 1,027
- References
- 216
- Citations by year
- 2026: 102 · 2025: 99 · 2024: 138 · 2023: 104 · 2022: 105 · 2021: 171 · 2020: 116 · 2019: 89 · 2018: 68 · 2017: 33
- FWCI
- 11.11
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Neurology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Open Research Exeter (University of Exeter) (acceptedVersion)
- Figshare (submittedVersion)
- Research Portal (King's College London) (submittedVersion, other-oa)
- Funders
- South London and Maudsley NHS Foundation Trust
- National Institute for Health and Care Research
- King's College London
- Institute of Psychiatry, Psychology and Neuroscience, King’s College London
- National Institute of Neurological Disorders and Stroke (P50NS053488)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neurological diseases and metabolism
- Keywords
- Parkinson's disease, cognitive decline, Parkinson's disease dementia, mild cognitive impairment, cerebrospinal fluid biomarkers, amyloid-beta 42, Lewy body pathology, APOE ε4, GBA mutations, cognitive training, nootropic drugs
- MeSH terms
- Dementia, Humans, Parkinson Disease, Cognitive Dysfunction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
